Pharmacogenomic testing for major depressive disorder in British Columbia, Canada:Recommendations from a public deliberation

Pharmacogenomic (PGx) testing for major depressive disorder (MDD) can reduce healthcare spending and improve patient outcomes. However, concerns about health equity, data privacy, and secondary usage of data require deliberation. We sought recommendations from members of the general public for policymakers’ consideration.